Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Tian Yi Zhang, David Iberri et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 29